If you work in wound care billing, you've probably already felt the impact of this one. CMS completely restructured how Medicare pays for skin substitutes starting January 1, 2026 — and it's not a minor tweak. We're talking about a nearly 90% reduction in aggregate spending, a flat payment rate replacing the old ASP+6% model, and a new coding framework built around FDA regulatory categories.
Let's walk through what actually changed, why CMS made these moves, and — most importantly — what your practice needs to do right now to stay compliant and protect whatever margin remains. For a deeper dive into the CMS final rule itself, check out our full analysis on Skin Substitute Reimbursement in 2026: CMS Final Rule Explained for Wound Care Practices.
Why Did CMS Cut Skin Substitute Payments So Dramatically?
Here's the short version: Medicare Part B spending on skin substitutes went from $252 million in 2019 to over $10 billion in 2024. That's a nearly 40-fold increase in five years — while patient volume only doubled. CMS concluded that the old ASP+6% payment model was creating perverse incentives: manufacturers could set high list prices, providers could bill generous markups, and the program bore the cost.
So CMS reclassified most skin substitutes as "incident-to supplies" under the Physician Fee Schedule. That single change pulled these products out of the ASP drug-pricing framework and into a flat-rate supply payment model. The result? A single national payment rate of $127.28 per square centimeter for nearly all skin substitute products in 2026, regardless of brand or acquisition cost.
The New FDA-Based Product Categories
CMS now categorizes skin substitutes by their FDA regulatory pathway — not by brand name or clinical indication. This matters because the HCPCS code you bill must match the product's FDA classification. Any mismatch increases audit risk. For compliance guidance around wound care LCDs and documentation, see our resource on Advanced Wound Care LCDs and Compliance.